Amplia Therapeutics announced promising opportunities for its FAK inhibitor narmafotinib in combination with KRAS inhibitors following new data from the 2026 ASCO meeting showing improved survival in pancreatic cancer. Narmafotinib enhances KRAS inhibitor effectiveness by blocking resistance pathways and addressing tumor fibrosis and immune suppression, common challenges in pancreatic cancer treatment. The drug also shows strong standalone results in clinical trials, with a 35% response rate and favorable survival outcomes. Amplia is advancing registration trials and exploring partnerships to develop combination therapies, aiming to improve treatment options for this hard-to-treat cancer.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
